125742 S1 M5 c4591001 A report cci any malignancy

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 16 Plus Documents

16

Document text

CCI_Any malignancy
MedDRA Dictionary Version: 230
Status: ACTIVETerm Name: CCI_Any malignancyCode: 90002950Extension: CCIReport Date/Time: 27-Oct-2020:10:42:05 AM EDT
Term Code Level Category Weight Scope
Ovarian germ cell embryonal carcinoma stage I 10033196 PT
Ovarian germ cell choriocarcinoma stage IV 10033195 PTOvarian germ cell choriocarcinoma stage III 10033191 PTOvarian germ cell choriocarcinoma stage II 10033187 PTOvarian germ cell choriocarcinoma stage I 10033183 PTOvarian germ cell choriocarcinoma 10073262 PTOvarian germ cell cancer stage IV 10061897 PTOvarian germ cell cancer stage III 10061896 PTOvarian germ cell cancer stage II 10061895 PTOvarian germ cell cancer stage I 10061894 PTLip and/or oral cavity cancer 10061523 PTLinitis plastica 10024520 PTLight chain disease 10024459 PTLeptomeningeal myelomatosis 10078282 PTLeiomyosarcoma recurrent 10024194 PTLeiomyosarcoma 10024189 PTLaryngeal squamous cell carcinoma 10023856 PTLaryngeal cancer stage IV 10023833 PTLaryngeal cancer stage III 10023832 PTLaryngeal cancer stage II 10023831 PTLaryngeal cancer stage I 10023830 PTLaryngeal cancer stage 0 10023829 PTLaryngeal cancer recurrent 10023828 PTLaryngeal cancer 10023825 PTLarge cell lung cancer stage IV 10023780 PTLarge cell lung cancer stage III 10023779 PTLarge cell lung cancer stage II 10023778 PTLarge cell lung cancer stage I 10023777 PTLarge cell lung cancer stage 0 10023776 PTLarge cell lung cancer recurrent 10023775 PTLarge cell lung cancer 10023774 PTLangerhans' cell histiocytosis 10069698 PTKeratinising squamous cell carcinoma of nasopharynx 10073324 PTKaposi's sarcoma classical type 10023288 PTKaposi's sarcoma 10023284 PTAdenosquamous cell lung cancer stage 0 10001248 PTAdenosquamous cell lung cancer recurrent 10001247 PTAdenosquamous cell lung cancer 10001245 PTAdenosquamous cell carcinoma 10068873 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023879
Adenosquamous carcinoma of vagina 10073978 PT
Adenosquamous carcinoma of the cervix 10001244 PT
Adenoid cystic carcinoma of salivary gland 10073370 PTExternal ear neoplasm malignant 10082277 PTAdenoid cystic carcinoma 10053231 PTAdenocarcinoma pancreas 10052747 PTAdenocarcinoma of the cervix 10001197 PTAdenocarcinoma of salivary gland 10068068 PTAdenocarcinoma of colon 10001167 PTAdenocarcinoma of appendix 10073359 PTAdenocarcinoma gastric 10001150 PTAdenocarcinoma 10001141 PTAcinic cell carcinoma of salivary gland 10073369 PTAcinar cell carcinoma of pancreas 10073363 PTAbdominal wall neoplasm malignant 10071023 PTYolk sac tumour site unspecified 10048251 PTVulvar adenocarcinoma 10063536 PTVulval cancer stage IV 10047749 PTVulval cancer stage III 10047748 PTVulval cancer stage II 10047747 PTVulval cancer stage I 10047746 PTVulval cancer stage 0 10047745 PTVulval cancer recurrent 10047744 PTVulval cancer 10047741 PTVaginal cancer stage IVB 10046895 PTVaginal cancer stage IVA 10046894 PTVaginal cancer stage III 10046893 PTVaginal cancer stage II 10046892 PTVaginal cancer stage I 10046891 PTVaginal cancer stage 0 10046890 PTVaginal cancer recurrent 10046889 PTVaginal cancer 10046885 PTVaginal adenocarcinoma 10065349 PTUterine carcinoma in situ 10046770 PTUterine cancer 10046766 PTUrinary tract carcinoma in situ 10061396 PTUrinary bladder sarcoma 10051690 PTUrethral cancer recurrent 10046435 PTUrethral cancer 10046431 PTUreteric cancer regional 10046397 PTUreteric cancer recurrent 10046396 PTUreteric cancer local 10046393 PTUreteric cancer 10046392 PTUndifferentiated sarcoma 10045515 PTUndifferentiated nasopharyngeal carcinoma 10073328 PTUndifferentiated carcinoma of colon 10073362 PTTumour of ampulla of Vater 10073851 PTTumour invasion 10064390 PTTumour budding 10076969 PTTubular breast carcinoma 10073104 PTTriple negative breast cancer 10075566 PTTransitional cell carcinoma urethra 10044426 PTTransitional cell carcinoma recurrent 10077051 PTOvarian germ cell cancer 10061893 PTOvarian epithelial cancer stage IV 10033164 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023880
Ovarian epithelial cancer stage III 10033163 PT
Ovarian epithelial cancer stage II 10033162 PT
Ovarian epithelial cancer stage I 10033161 PT
Ovarian epithelial cancer recurrent 10033160 PT
Ovarian epithelial cancer 10061328 PT
Ovarian endometrioid carcinoma 10073269 PT
Ovarian embryonal carcinoma 10056266 PT
Ovarian dysgerminoma stage unspecified 10052759 PT
Ovarian dysgerminoma stage IV 10033156 PT
Ovarian dysgerminoma stage III 10033152 PT
Ovarian dysgerminoma stage II 10033148 PT
Ovarian dysgerminoma stage I 10033144 PT
Ovarian clear cell carcinoma 10073268 PT
Ovarian cancer stage IV 10070908 PT
Ovarian cancer stage III 10070907 PT
Ovarian cancer stage II 10070906 PT
Ovarian cancer stage I 10070905 PT
Ovarian cancer recurrent 10066697 PT
Ovarian cancer 10033128 PT
Osteosarcoma recurrent 10031296 PT
Osteosarcoma 10031291 PT
Oropharyngeal squamous cell carcinoma 10031112 PT
Oropharyngeal lymphoepithelioma 10031104 PT
Oropharyngeal cancer stage IV 10064099 PT
Oropharyngeal cancer stage III 10031102 PT
Oropharyngeal cancer stage II 10031101 PT
Oropharyngeal cancer stage I 10031100 PT
Oropharyngeal cancer stage 0 10031099 PT
Oropharyngeal cancer recurrent 10031098 PT
Oropharyngeal cancer 10031096 PT
Optic glioma 10073338 PT
Oligodendroglioma 10030286 PT
Oligoastrocytoma 10073131 PT
Hormone receptor positive breast cancer 10083234 PT
Oesophageal squamous cell carcinoma stage IV 10030192 PT
Oesophageal squamous cell carcinoma stage III 10030191 PT
Oesophageal squamous cell carcinoma stage II 10030190 PT
Oesophageal squamous cell carcinoma stage I 10030189 PT
Oesophageal squamous cell carcinoma stage 0 10030188 PT
Oesophageal squamous cell carcinoma recurrent 10030187 PT
Oesophageal squamous cell carcinoma 10061534 PT
Oesophageal carcinoma stage 0 10030162 PT
Oesophageal carcinoma recurrent 10030159 PT
Oesophageal carcinoma 10030155 PT
Oesophageal adenocarcinoma stage IV 10030145 PT
Oesophageal adenocarcinoma stage III 10030144 PT
Oesophageal adenocarcinoma stage II 10030143 PT
Oesophageal adenocarcinoma stage I 10030142 PT
Oesophageal adenocarcinoma stage 0 10030141 PT
Oesophageal adenocarcinoma recurrent 10030140 PT
Oesophageal adenocarcinoma 10030137 PT
Ocular haemangiopericytoma 10057416 PT
NUT midline carcinoma 10078295 PT
Non-small cell lung cancer stage IV 10029522 PT
Non-small cell lung cancer stage IIIB 10029521 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023881
Non-small cell lung cancer stage IIIA 10029520 PT
Non-small cell lung cancer stage III 10029519 PT
Non-small cell lung cancer stage II 10029518 PT
Non-small cell lung cancer stage I 10029517 PT
Non-small cell lung cancer stage 0 10029516 PT
Non-small cell lung cancer recurrent 10029515 PT
Non-small cell lung cancer 10061873 PT
Non-secretory adenoma of pituitary 10029556 PTNon-renal cell carcinoma of kidney 10061872 PTNonkeratinising carcinoma of nasopharynx 10073325 PTNongerminomatous germ cell tumour of the CNS 10065871 PTNeurofibrosarcoma recurrent 10029277 PTInflammatory carcinoma of breast recurrent 10021977 PTImmune reconstitution inflammatory syndrome associated Kaposi's sarcoma 10072796 PTHypopharyngeal cancer stage IV 10021049 PTHypopharyngeal cancer stage III 10021048 PTHypopharyngeal cancer stage II 10021047 PTHypopharyngeal cancer stage I 10021046 PTHypopharyngeal cancer stage 0 10021045 PTHypopharyngeal cancer recurrent 10021044 PTHypopharyngeal cancer 10021042 PTHuerthle cell carcinoma 10066136 PTHormone-refractory prostate cancer 10062904 PTHormone-dependent prostate cancer 10071119 PTHormone refractory breast cancer 10076935 PTHistiocytic sarcoma 10076876 PTHistiocytic medullary reticulosis 10068785 PTHER2 positive gastric cancer 10066896 PTHER2 positive breast cancer 10065430 PTHepatocellular carcinoma 10073071 PTHepatoblastoma recurrent 10019823 PTHepatoblastoma 10062001 PTHepatobiliary cancer in situ 10073074 PTHepatobiliary cancer 10073073 PTHepatic cancer stage IV 10059325 PTHepatic cancer stage III 10059324 PTHepatic cancer stage II 10059319 PTHepatic cancer stage I 10059318 PTHepatic cancer recurrent 10073070 PTHepatic cancer 10073069 PTHepatic angiosarcoma 10067388 PTHeavy chain disease 10019350 PTHead and neck cancer stage IV 10071536 PTHead and neck cancer stage III 10071537 PTHead and neck cancer stage II 10071538 PTHead and neck cancer stage I 10071539 PTHead and neck cancer 10067821 PTHaematological malignancy 10066476 PTHaemangiopericytoma of meninges 10018826 PTHaemangiopericytoma 10018825 PTGlottis carcinoma 10018395 PTGliosarcoma 10018340 PTGliomatosis cerebri 10066254 PTGlioma 10018338 PTGlioblastoma multiforme 10018337 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023882
Transitional cell carcinoma 10044412 PT
Transitional cell cancer of the renal pelvis and ureter regional 10044411 PT
Transitional cell cancer of the renal pelvis and ureter recurrent 10044410 PT
Transitional cell cancer of the renal pelvis and ureter localised 10044408 PT
Transitional cell cancer of the renal pelvis and ureter 10044407 PT
Tracheal cancer 10044285 PT
Tonsil cancer 10044002 PT
Tongue neoplasm malignant stage unspecified 10043966 PT
Tongue carcinoma stage IV 10058433 PT
Tongue carcinoma stage III 10058432 PT
Tongue carcinoma stage II 10058431 PT
Tongue carcinoma stage I 10058430 PT
Tongue carcinoma stage 0 10058429 PT
Tongue cancer recurrent 10071251 PT
Thyroid cancer stage IV 10071030 PT
Thyroid cancer stage III 10071029 PT
Thyroid cancer stage II 10071028 PT
Thyroid cancer stage I 10071027 PT
Thyroid cancer stage 0 10070567 PT
Thyroid cancer recurrent 10072162 PT
Thyroid cancer 10066474 PT
Thymoma malignant recurrent 10043674 PT
Thymoma malignant 10061031 PT
Throat cancer 10043515 PT
Testis cancer recurrent 10069813 PT
Testis cancer 10057644 PT
Testicular yolk sac tumour stage III 10043359 PT
Testicular yolk sac tumour stage II 10043358 PT
Glioblastoma 10018336 PT
Gingival cancer 10067807 PT
Germ cell cancer 10061184 PT
Genitourinary melanoma 10077166 PT
Genital neoplasm malignant female 10018160 PT
Genital cancer male in situ 10073124 PT
Genital cancer male 10073116 PT
Gastrooesophageal cancer 10062878 PT
Gastrointestinal stromal tumour 10051066 PT
Gastrointestinal melanoma 10077167 PT
Gastrointestinal carcinoma in situ 10061168 PT
Gastrointestinal carcinoma 10017940 PT
Gastrinoma malignant 10051709 PT
Gastric sarcoma 10055008 PT
Colon cancer stage 0 10063523 PT
Colon cancer recurrent 10009952 PT
Colon cancer 10009944 PT
CNS germinoma 10065852 PT
Clear cell sarcoma of the kidney 10009253 PT
Clear cell sarcoma of soft tissue 10073140 PT
Clear cell renal cell carcinoma 10073251 PT
Clear cell endometrial carcinoma 10009252 PT
Testicular yolk sac tumour stage I 10043357 PT
Testicular yolk sac tumour 10073121 PT
Testicular seminoma (pure) stage III 10043352 PT
Testicular seminoma (pure) stage II 10043351 PT
Testicular seminoma (pure) stage I 10043350 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023883
Testicular seminoma (pure) 10062124 PT
Testicular malignant teratoma stage III 10043341 PT
Testicular malignant teratoma stage II 10043340 PT
Testicular malignant teratoma stage I 10043339 PT
Testicular malignant teratoma 10073120 PT
Extragonadal primary seminoma (pure) stage I 10015811 PT
Extragonadal primary seminoma (pure) 10073057 PT
Extragonadal primary non-seminoma stage IV 10015810 PT
Extragonadal primary non-seminoma stage III 10015809 PT
Extragonadal primary non-seminoma stage II 10015806 PT
Extragonadal primary non-seminoma stage I 10015805 PT
Extragonadal primary non-seminoma 10061849 PT
Testicular leiomyosarcoma 10057340 PT
Testicular germ cell tumour mixed stage III 10043333 PT
Testicular germ cell tumour mixed stage II 10043332 PT
Testicular germ cell tumour mixed stage I 10043331 PT
Testicular germ cell tumour mixed 10073119 PT
Testicular germ cell cancer 10061378 PT
Testicular embryonal carcinoma stage III 10043311 PT
Testicular embryonal carcinoma stage II 10043310 PT
Testicular embryonal carcinoma stage I 10043309 PT
Testicular embryonal carcinoma 10062123 PT
Testicular choriocarcinoma stage III 10043305 PT
Testicular choriocarcinoma stage II 10043304 PT
Testicular choriocarcinoma stage I 10043303 PT
Testicular choriocarcinoma recurrent 10069812 PT
Testicular choriocarcinoma 10062122 PT
Synovial sarcoma recurrent 10042867 PT
Synovial sarcoma 10042863 PT
Stewart-Treves syndrome 10059498 PT
Squamous endometrial carcinoma 10041883 PT
Squamous cell carcinoma of the vulva 10041875 PT
Squamous cell carcinoma of the vagina 10041866 PT
Squamous cell carcinoma of the tongue 10041865 PT
Squamous cell carcinoma of the oral cavity 10041857 PT
Squamous cell carcinoma of the hypopharynx 10041849 PT
Squamous cell carcinoma of the cervix 10041848 PT
Squamous cell carcinoma of pharynx 10066471 PT
Squamous cell carcinoma of lung 10041826 PT
Squamous cell carcinoma of head and neck 10060121 PT
Spindle cell sarcoma 10049067 PT
Spinal meningioma malignant 10041580 PT
Spermatocytic seminoma 10073118 PT
Somatostatinoma 10041329 PT
Solid pseudopapillary tumour of the pancreas 10069345 PT
Soft tissue sarcoma 10075333 PT
Small intestine leiomyosarcoma 10041127 PT
Small intestine carcinoma stage IV 10059372 PT
Small intestine carcinoma stage III 10059371 PT
Small intestine carcinoma stage II 10059370 PT
Small intestine carcinoma stage I 10059369 PT
Small intestine carcinoma stage 0 10059368 PT
Small intestine carcinoma recurrent 10041124 PT
Small intestine carcinoma 10054184 PT
Small intestine adenocarcinoma 10073373 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023884
Small cell lung cancer recurrent 10041070 PT
Small cell lung cancer limited stage 10041069 PT
Small cell lung cancer extensive stage 10041068 PT
Small cell lung cancer 10041067 PT
Small cell carcinoma of the cervix 10041057 PT
Small cell carcinoma 10041056 PT
Signet-ring cell carcinoma 10057266 PT
Serous cystadenocarcinoma ovary 10054913 PT
Cystadenocarcinoma pancreas 10065908 PT
Seminoma 10039956 PT
Secretory adenoma of pituitary 10039893 PT
Second primary malignancy 10039801 PT
Scrotal cancer 10039744 PT
Sarcomatosis 10039500 PT
Clear cell carcinoma of cervix 10074909 PT
Choroid plexus carcinoma 10067478 PT
Choroid melanoma 10008773 PT
Choriocarcinoma 10008757 PT
Chordoma 10008747 PT
Chondrosarcoma recurrent 10008738 PT
Chondrosarcoma 10008734 PT
Cholangiosarcoma 10077861 PT
Cholangiocarcinoma 10008593 PT
Cervix carcinoma stage IV 10008348 PT
Cervix carcinoma stage III 10008347 PT
Cervix carcinoma stage II 10008346 PT
Cervix carcinoma stage I 10008345 PT
Cervix carcinoma stage 0 10061809 PT
Cervix carcinoma recurrent 10008344 PT
Cervix carcinoma 10008342 PT
Central nervous system neuroblastoma 10073130 PT
Central nervous system melanoma 10077160 PT
Cardiac teratoma 10057456 PT
Cardiac neoplasm malignant 10061025 PT
Carcinoma in situ of trachea 10007401 PT
Carcinoma in situ of penis 10007384 PT
Carcinoma in situ of eye 10007368 PT
Carcinoma in situ 10061450 PT
Carcinoma ex-pleomorphic adenoma 10077435 PT
Cancer in remission 10065305 PT
Bronchioloalveolar carcinoma 10058354 PT
Bronchial carcinoma 10006417 PT
Breast sarcoma recurrent 10068584 PT
Breast sarcoma 10068582 PT
Renal cancer recurrent 10038390 PT
Renal cancer 10038389 PT
Refractory cancer 10070308 PT
Recurrent cancer 10038111 PT
Rectosigmoid cancer stage IV 10038099 PT
Rectosigmoid cancer stage III 10038098 PT
Rectosigmoid cancer stage II 10038097 PT
Rectosigmoid cancer stage I 10038096 PT
Neuroendocrine carcinoma of the bladder 10078341 PT
Neuroendocrine carcinoma 10057270 PT
Neuroblastoma recurrent 10066595 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023885
Neuroblastoma 10029260 PT
Nephroblastoma 10029145 PT
Neoplasm malignant 10028997 PT
Nasopharyngeal cancer stage IV 10028792 PTNasopharyngeal cancer stage III 10028791 PTNasopharyngeal cancer stage II 10028790 PTNasopharyngeal cancer stage I 10028789 PTNasopharyngeal cancer stage 0 10028788 PTNasopharyngeal cancer recurrent 10028787 PTNasopharyngeal cancer 10061306 PTNasal sinus cancer 10028767 PTNasal cavity cancer 10028729 PTMyxoid liposarcoma 10073137 PTMyxofibrosarcoma 10066948 PTMyelofibrosis 10028537 PTMyeloblastoma 10051141 PTMusculoskeletal cancer 10077675 PTMultiple endocrine neoplasia Type 2 10073149 PTMueller's mixed tumour 10066057 PTMucoepidermoid carcinoma of salivary gland 10073371 PTMucoepidermoid carcinoma 10057269 PTMucinous endometrial carcinoma 10028076 PTMalignant respiratory tract neoplasm 10061270 PTMalignant polyp 10078695 PTMalignant pituitary tumour 10026672 PTMalignant peritoneal neoplasm 10061269 PTMalignant pericardial neoplasm 10054946 PTMalignant palate neoplasm 10026663 PTMalignant ovarian cyst 10026662 PTMalignant oligodendroglioma 10026659 PTMalignant nipple neoplasm male 10053128 PTMalignant nipple neoplasm female 10053129 PTMalignant nipple neoplasm 10062051 PTMalignant nervous system neoplasm 10061268 PTMalignant neoplasm progression 10051398 PTMalignant neoplasm papilla of Vater 10077303 PTMalignant neoplasm of uterine adnexa 10026616 PTMalignant neoplasm of unknown primary site 10073059 PTMalignant neoplasm of thymus 10026533 PTMalignant neoplasm of thorax 10026532 PTMalignant neoplasm of spinal cord 10026472 PTMalignant neoplasm of spermatic cord 10026470 PTMalignant neoplasm of seminal vesicle 10068124 PTMalignant neoplasm of retina 10026432 PTMalignant neoplasm of renal pelvis 10026426 PTMalignant neoplasm of pleura 10026351 PTMalignant neoplasm of placenta 10026350 PTMalignant neoplasm of paraurethral glands 10026326 PTMalignant neoplasm of orbit 10026183 PTMalignant neoplasm of lacrimal gland 10026031 PTMalignant neoplasm of lacrimal duct 10026030 PTMalignant neoplasm of islets of Langerhans 10025997 PTMalignant neoplasm of eyelid 10063693 PTMalignant neoplasm of eye 10025910 PTMalignant neoplasm of cornea 10025871 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023886
Malignant neoplasm of conjunctiva 10025861 PT
Malignant neoplasm of choroid 10025839 PT
Malignant neoplasm of ampulla of Vater 10025697 PT
Malignant muscle neoplasm 10062050 PTMalignant middle ear neoplasm 10061267 PTMalignant mesenteric neoplasm 10067369 PTMalignant mesenchymoma recurrent 10025677 PTMalignant mesenchymoma 10061526 PTMalignant melanoma of sites other than skin 10025654 PTMalignant melanoma of eyelid 10063706 PTMalignant melanoma 10025650 PTMalignant mediastinal neoplasm 10061241 PTMalignant mast cell neoplasm 10025638 PTMalignant joint neoplasm 10078145 PTMalignant hydatidiform mole 10025598 PTMalignant histiocytosis 10025581 PTMalignant haemangiopericytoma recurrent 10025570 PTMalignant haemangiopericytoma 10025566 PTMalignant glioma 10065443 PTMalignant giant cell fibrous histiocytoma 10073141 PTMalignant genitourinary tract neoplasm 10074419 PTMalignant fibrous histiocytoma recurrent 10025561 PTMalignant fibrous histiocytoma of bone 10025557 PTMalignant fibrous histiocytoma 10025552 PTMalignant cranial nerve neoplasm 10061238 PTMalignant connective tissue neoplasm 10074340 PTMalignant anorectal neoplasm 10061237 PTLymphangiosarcoma 10025223 PTLung squamous cell carcinoma stage IV 10025125 PTLung squamous cell carcinoma stage III 10025124 PTLung squamous cell carcinoma stage II 10025123 PTLung squamous cell carcinoma stage I 10025122 PTLung squamous cell carcinoma stage 0 10025121 PTLung squamous cell carcinoma recurrent 10025120 PTLung neoplasm malignant 10058467 PTLung infiltration malignant 10062041 PTLung carcinoma cell type unspecified stage IV 10025070 PTLung carcinoma cell type unspecified stage III 10025069 PTLung carcinoma cell type unspecified stage II 10025068 PTLung carcinoma cell type unspecified stage I 10025067 PTLung carcinoma cell type unspecified stage 0 10025066 PTLung carcinoma cell type unspecified recurrent 10025065 PTLung adenocarcinoma stage IV 10025038 PTLung adenocarcinoma stage III 10025037 PTLung adenocarcinoma stage II 10025036 PTLung adenocarcinoma stage I 10025035 PTLung adenocarcinoma stage 0 10025034 PTLung adenocarcinoma recurrent 10025033 PTLung adenocarcinoma 10025031 PTLobular breast carcinoma in situ 10073099 PTLiver carcinoma ruptured 10050842 PTLiposarcoma recurrent 10024632 PTLiposarcoma 10024627 PTLip squamous cell carcinoma 10064055 PTMucinous cystadenocarcinoma ovary 10054914 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023887
Mucinous breast carcinoma 10073101 PT
Mucinous adenocarcinoma of appendix 10073361 PT
Mixed-type liposarcoma 10073136 PT
Mixed hepatocellular cholangiocarcinoma 10027761 PT
Mixed adenoneuroendocrine carcinoma 10076748 PT
Metaplastic breast carcinoma 10073100 PT
Extragonadal primary malignant teratoma 10061848 PT
Extragonadal primary embryonal carcinoma 10015789 PT
Ewing's sarcoma recurrent 10015564 PT
Ewing's sarcoma 10015560 PT
Erythroplasia of vulva 10052825 PT
Lip neoplasm malignant stage unspecified 10024557 PT
Lip and/or oral cavity cancer stage IV 10024540 PT
Lip and/or oral cavity cancer stage III 10024539 PT
Lip and/or oral cavity cancer stage II 10024538 PT
Lip and/or oral cavity cancer stage I 10024537 PT
Lip and/or oral cavity cancer stage 0 10024536 PT
Lip and/or oral cavity cancer recurrent 10024535 PT
Gastric cancer stage IV 10061967 PT
Gastric cancer stage III 10017765 PT
Gastric cancer stage II 10017764 PT
Gastric cancer stage I 10017763 PT
Gastric cancer stage 0 10017762 PT
Gastric cancer recurrent 10017761 PT
Gastric cancer 10017758 PT
Ganglioneuroblastoma 10017708 PT
Ganglioglioma 10017701 PT
Gallbladder squamous cell carcinoma 10073068 PT
Gallbladder cancer stage IV 10058283 PT
Gallbladder cancer stage III 10058282 PT
Gallbladder cancer stage II 10058281 PT
Gallbladder cancer stage I 10059317 PT
Gallbladder cancer stage 0 10059316 PT
Gallbladder cancer recurrent 10017619 PT
Gallbladder cancer 10017614 PT
Gallbladder adenosquamous carcinoma 10073067 PT
Gallbladder adenocarcinoma 10058286 PT
Follicular thyroid cancer 10016935 PT
Follicular dendritic cell sarcoma 10075332 PT
Fibrosarcoma 10016632 PT
Female reproductive tract carcinoma in situ 10061154 PT
Fallopian tube cancer stage IV 10016187 PT
Fallopian tube cancer stage III 10016186 PT
Fallopian tube cancer stage II 10016185 PT
Fallopian tube cancer stage I 10016184 PT
Fallopian tube cancer 10016180 PT
Extraskeletal osteosarcoma recurrent 10015852 PT
Extraskeletal osteosarcoma 10015847 PT
Extraskeletal myxoid chondrosarcoma 10073134 PT
Extraskeletal chondrosarcoma recurrent 10015843 PT
Extra-osseous Ewing's sarcoma recurrent 10015764 PT
Extra-osseous Ewing's sarcoma 10015759 PT
Extraocular retinoblastoma 10015831 PT
Extragonadal primary seminoma (pure) stage IV 10015816 PT
Extragonadal primary seminoma (pure) stage III 10015815 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023888
Extragonadal primary seminoma (pure) stage II 10015812 PT
Erythroplasia of lip 10052826 PT
Erythroblastosis 10049466 PT
Epithelioid sarcoma recurrent 10015104 PT
Epithelioid sarcoma 10015099 PT
Epithelioid mesothelioma 10073064 PT
Epiglottic cancer 10084056 PT
Epididymal cancer 10073115 PT
Ependymoma malignant 10014968 PT
Ependymoma 10014967 PT
Endotheliomatosis 10076868 PT
Endometrial stromal sarcoma 10048397 PT
Endometrial sarcoma recurrent 10067064 PT
Endometrial sarcoma 10057649 PT
Endometrial cancer stage IV 10014741 PT
Endometrial cancer stage III 10014740 PT
Endometrial cancer stage II 10014739 PT
Endometrial cancer stage I 10014738 PT
Endometrial cancer stage 0 10014737 PT
Endometrial cancer recurrent 10014736 PT
Endometrial cancer 10014733 PT
Endometrial adenocarcinoma 10014720 PT
Endocrine neoplasm malignant 10061122 PT
Embryonal rhabdomyosarcoma 10065868 PT
Ear neoplasm malignant 10055017 PT
Ductal adenocarcinoma of pancreas 10073364 PT
Desmoplastic small round cell tumour 10064581 PT
Desmoplastic mesothelioma 10073063 PT
Dermatofibrosarcoma protuberans 10057070 PT
Dedifferentiated liposarcoma 10073135 PT
Cystadenocarcinoma ovary 10054912 PT
Craniopharyngioma 10011318 PT
Conjunctival primary acquired melanosis 10066925 PT
Conjunctival melanoma 10066384 PT
Colorectal carcinoma stage 0 10010038 PT
Colorectal cancer stage IV 10010035 PT
Colorectal cancer stage III 10010034 PT
Colorectal cancer stage II 10010033 PT
Colorectal cancer stage I 10010032 PT
Colorectal cancer recurrent 10010030 PT
Colorectal cancer 10061451 PT
Colorectal adenocarcinoma 10052360 PT
Colon cancer stage IV 10009956 PT
Colon cancer stage III 10009955 PT
Colon cancer stage II 10009954 PT
Colon cancer stage I 10009953 PT
Mesothelioma malignant recurrent 10027411 PT
Mesothelioma malignant 10027407 PT
Meningioma malignant 10027193 PT
Medulloblastoma recurrent 10066594 PT
Medulloblastoma 10027107 PT
Medullary thyroid cancer 10027105 PT
Medullary carcinoma of breast 10027095 PT
Malignant urinary tract neoplasm 10061272 PT
Malignant transformation 10064912 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023889
Malignant splenic neoplasm 10026702 PT
Iris melanoma 10073086 PT
Invasive papillary breast carcinoma 10073098 PT
Invasive lobular breast carcinoma 10073096 PT
Invasive ductal breast carcinoma 10073095 PT
Invasive breast carcinoma 10075713 PT
Intraosseous angioma 10048846 PT
Intraocular melanoma 10061252 PT
Intraductal proliferative breast lesion 10073094 PT
Intraductal papillary-mucinous carcinoma of pancreas 10073365 PT
Intracranial meningioma malignant 10022770 PT
Intracranial germ cell tumour 10073751 PT
Intestinal adenocarcinoma 10051925 PT
Inflammatory malignant fibrous histiocytoma 10073142 PT
Breast cancer stage IV 10006202 PT
Breast cancer stage III 10006201 PT
Breast cancer stage II 10006200 PT
Breast cancer stage I 10006199 PT
Breast cancer recurrent 10006198 PT
Breast cancer male 10061020 PT
Breast cancer in situ 10006189 PT
Sarcomatoid mesothelioma 10073065 PT
Sarcoma uterus 10039497 PT
Sarcoma of skin 10039495 PT
Sarcoma 10039491 PT
Salivary gland cancer stage IV 10039403 PT
Salivary gland cancer stage III 10039402 PT
Salivary gland cancer stage II 10039401 PT
Salivary gland cancer stage I 10039400 PT
Salivary gland cancer stage 0 10039399 PT
Salivary gland cancer recurrent 10039398 PT
Salivary gland cancer 10061934 PT
Round cell liposarcoma 10073139 PT
Rhabdomyosarcoma recurrent 10039027 PT
Rhabdomyosarcoma 10039022 PT
Rhabdoid tumour of the kidney 10039019 PT
Rhabdoid tumour 10073334 PT
Retroperitoneal cancer 10038977 PT
Retinoblastoma 10038916 PT
Retinal melanoma 10038878 PT
Respiratory tract carcinoma in situ 10038724 PT
Renal cell carcinoma stage IV 10038414 PT
Renal cell carcinoma stage III 10038413 PT
Renal cell carcinoma stage II 10038412 PT
Renal cell carcinoma stage I 10038411 PT
Renal cell carcinoma recurrent 10038410 PT
Renal cell carcinoma 10067946 PT
Renal cancer stage IV 10038394 PT
Renal cancer stage III 10038393 PT
Renal cancer stage II 10038392 PT
Renal cancer stage I 10038391 PT
Inflammatory carcinoma of the breast 10021980 PT
Inflammatory carcinoma of breast stage IV 10021979 PT
Inflammatory carcinoma of breast stage III 10021978 PT
Rectosigmoid cancer stage 0 10038095 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023890
Rectosigmoid cancer recurrent 10038094 PT
Rectosigmoid cancer 10038086 PT
Rectal cancer stage IV 10038051 PT
Rectal cancer stage III 10038050 PT
Rectal cancer stage II 10038049 PT
Rectal cancer stage I 10038048 PT
Rectal cancer stage 0 10038047 PT
Rectal cancer recurrent 10038046 PT
Rectal cancer 10038038 PT
Rectal adenocarcinoma 10038019 PT
Prostate cancer stage IV 10036920 PT
Prostate cancer stage III 10036919 PT
Prostate cancer stage II 10036918 PT
Prostate cancer stage I 10036917 PT
Prostate cancer stage 0 10036912 PT
Prostate cancer recurrent 10036911 PT
Prostate cancer 10060862 PT
Primitive neuroectodermal tumour 10057846 PT
Penis carcinoma stage I 10034332 PT
Penis carcinoma recurrent 10034331 PT
Penile squamous cell carcinoma 10059631 PT
Penile cancer 10034299 PT
Parathyroid tumour malignant 10033965 PT
Paranasal sinus and nasal cavity malignant neoplasm stage IV 10033860 PT
Paranasal sinus and nasal cavity malignant neoplasm stage III 10033859 PT
Paranasal sinus and nasal cavity malignant neoplasm stage II 10033858 PT
Paranasal sinus and nasal cavity malignant neoplasm stage I 10033857 PT
Paranasal sinus and nasal cavity malignant neoplasm stage 0 10033856 PT
Paranasal sinus and nasal cavity malignant neoplasm recurrent 10033855 PT
Paranasal sinus and nasal cavity malignant neoplasm 10061909 PT
Paraganglion neoplasm malignant 10033791 PT
Papillary thyroid cancer 10033701 PT
Papillary serous endometrial carcinoma 10033700 PT
Papillary renal cell carcinoma 10078493 PT
Pancreatoblastoma 10073367 PT
Pancreatic sarcoma 10055006 PT
Pancreatic carcinoma stage IV 10059326 PT
Pancreatic carcinoma stage III 10059323 PT
Pancreatic carcinoma stage II 10059322 PT
Pancreatic carcinoma stage I 10059321 PT
Pancreatic carcinoma stage 0 10059320 PT
Pancreatic carcinoma recurrent 10033613 PT
Pancreatic carcinoma 10033609 PT
Pancoast's tumour 10033572 PT
Paget's disease of the vulva 10033369 PT
Paget's disease of penis 10033365 PT
Paget's disease of nipple 10033364 PT
Ovarian stromal cancer 10065858 PT
Ovarian low malignant potential tumour 10033268 PT
Ovarian germ cell tumour mixed 10073259 PT
Ovarian germ cell teratoma stage IV 10033249 PT
Ovarian germ cell teratoma stage III 10033245 PT
Ovarian germ cell teratoma stage II 10033241 PT
Ovarian germ cell teratoma stage I 10033237 PT
Ovarian germ cell teratoma 10073265 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023891
Ovarian germ cell polyembryoma stage IV 10033235 PT
Ovarian germ cell polyembryoma stage III 10033231 PT
Ovarian germ cell polyembryoma stage II 10033227 PT
Ovarian germ cell polyembryoma stage I 10033223 PTOvarian germ cell polyembryoma 10073264 PTOvarian germ cell endodermal sinus tumour stage IV 10033221 PTOvarian germ cell endodermal sinus tumour stage III 10033220 PTOvarian germ cell endodermal sinus tumour stage II 10033219 PTOvarian germ cell endodermal sinus tumour stage I 10033218 PTOvarian germ cell endodermal sinus tumour 10073263 PTOvarian germ cell embryonal carcinoma stage IV 10033208 PTOvarian germ cell embryonal carcinoma stage III 10033204 PTOvarian germ cell embryonal carcinoma stage II 10033200 PTBreast cancer female 10057654 PTBreast cancer 10006187 PTBreast angiosarcoma 10072813 PTBrain teratoma 10068394 PTBrain stem glioma 10006143 PTBrain sarcoma 10073857 PTBrain neoplasm malignant 10006131 PTBorderline serous tumour of ovary 10073267 PTBorderline ovarian tumour 10006032 PTBorderline mucinous tumour of ovary 10073266 PTBone sarcoma 10006007 PTBone marrow tumour cell infiltration 10049556 PTBone giant cell tumour malignant 10073106 PTBone cancer 10005949 PTBladder transitional cell carcinoma stage IV 10066752 PTBladder transitional cell carcinoma stage III 10066754 PTBladder transitional cell carcinoma stage II 10066753 PTBladder transitional cell carcinoma stage I 10066751 PTBladder transitional cell carcinoma stage 0 10066749 PTBladder transitional cell carcinoma recurrent 10066750 PTBladder transitional cell carcinoma 10005084 PTBladder squamous cell carcinoma stage unspecified 10005081 PTBladder squamous cell carcinoma stage IV 10005080 PTBladder squamous cell carcinoma stage III 10005079 PTBladder squamous cell carcinoma stage II 10005078 PTBladder squamous cell carcinoma stage I 10005077 PTBladder squamous cell carcinoma stage 0 10005076 PTBladder squamous cell carcinoma recurrent 10005075 PTBladder cancer stage IV 10005012 PTBladder cancer stage III 10005011 PTBladder cancer stage II 10005010 PTBladder cancer stage I, without cancer in situ 10005009 PTBladder cancer stage I, with cancer in situ 10005008 PTBladder cancer stage 0, without cancer in situ 10005007 PTBladder cancer stage 0, with cancer in situ 10005006 PTBladder cancer recurrent 10005005 PTBladder cancer 10005003 PTBladder adenocarcinoma stage unspecified 10004992 PTBladder adenocarcinoma stage IV 10004991 PTBladder adenocarcinoma stage III 10004990 PTBladder adenocarcinoma stage II 10004989 PTBladder adenocarcinoma stage I 10004988 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023892
Bladder adenocarcinoma stage 0 10004987 PT
Bladder adenocarcinoma recurrent 10004986 PT
Biphasic mesothelioma 10073062 PT
Bile duct squamous cell carcinoma 10004633 PT
Bile duct cancer stage IV 10059376 PTBile duct cancer stage III 10059375 PTBile duct cancer stage II 10059374 PTBile duct cancer stage I 10059373 PTPostcricoid cancer 10036334 PTPoorly differentiated thyroid carcinoma 10076603 PTPolycythaemia vera 10036057 PTPleural sarcoma 10051950 PTPleural mesothelioma malignant recurrent 10035607 PTPleural mesothelioma malignant 10059518 PTPleural mesothelioma 10035603 PTPleomorphic malignant fibrous histiocytoma 10073143 PTPleomorphic liposarcoma 10073138 PTPlasmacytoma 10035484 PTPlasma cell myeloma recurrent 10073133 PTPlasma cell myeloma in remission 10073132 PTPlasma cell myeloma 10035226 PTPituitary neoplasm malignant recurrent 10057838 PTPinealoblastoma 10050487 PTPineal parenchymal neoplasm malignant 10061537 PTPineal germinoma 10035052 PTPharyngeal cancer stage IV 10034818 PTPharyngeal cancer stage III 10034817 PTPharyngeal cancer stage II 10034816 PTPharyngeal cancer stage I 10034815 PTPharyngeal cancer stage 0 10034814 PTPharyngeal cancer recurrent 10034813 PTPharyngeal cancer 10034811 PTPhaeochromocytoma malignant 10051710 PTPhaeochromocytoma crisis 10068778 PTPhaeochromocytoma 10034800 PTPeritoneal sarcoma 10051949 PTPeritoneal mesothelioma malignant recurrent 10034671 PTPeritoneal mesothelioma malignant 10056558 PTPeritoneal gliomatosis 10070561 PTPeripheral primitive neuroectodermal tumour of soft tissue 10073144 PTPeripheral primitive neuroectodermal bone tumour 10073107 PTPeripheral neuroepithelioma of soft tissue 10057646 PTPeripheral neuroepithelioma of bone recurrent 10034605 PTPeripheral neuroepithelioma of bone 10061342 PTNeurofibrosarcoma 10061527 PTPericardial mesothelioma malignant recurrent 10034480 PTPericardial mesothelioma malignant 10073066 PTPenis carcinoma stage IV 10034335 PTPenis carcinoma stage III 10034334 PTPenis carcinoma stage II 10034333 PTBile duct cancer stage 0 10059384 PTBile duct cancer recurrent 10004596 PTBile duct cancer 10004593 PTBile duct adenosquamous carcinoma 10004589 PTBile duct adenocarcinoma 10004585 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023893
Basosquamous carcinoma 10004178 PT
Atypical teratoid/rhabdoid tumour of CNS 10065907 PT
Astrocytoma malignant 10060971 PT
Astrocytoma 10003571 PT
APUDoma 10003069 PT
Appendix cancer 10073360 PT
Apocrine breast carcinoma 10066206 PT
Angiosarcoma recurrent 10002480 PT
Angiosarcoma non-metastatic 10057700 PT
Angiosarcoma 10002476 PT
Angiocentric glioma 10073129 PT
Anaplastic thyroid cancer 10002240 PT
Anaplastic oligodendroglioma 10073128 PT
Anaplastic meningioma 10073127 PT
Anaplastic astrocytoma 10002224 PT
Anal squamous cell carcinoma 10073358 PT
Anal cancer stage IV 10002138 PT
Anal cancer stage III 10002137 PT
Anal cancer stage II 10002136 PT
Anal cancer stage I 10002135 PT
Anal cancer stage 0 10002134 PT
Anal cancer recurrent 10002133 PT
Anal cancer 10061424 PT
Alveolar soft part sarcoma recurrent 10001887 PT
Alveolar soft part sarcoma 10001882 PT
Alveolar rhabdomyosarcoma 10065867 PT
Aesthesioneuroblastoma 10001433 PT
Adrenocortical carcinoma 10001388 PT
Adrenal gland cancer 10073152 PT
Adenosquamous cell lung cancer stage IV 10001254 PT
Adenosquamous cell lung cancer stage III 10001251 PT
Adenosquamous cell lung cancer stage II 10001250 PT
Adenosquamous cell lung cancer stage I 10001249 PT
090177e196edd21d\Final\Final On: 01-May-2021 00:12 (GMT)
FDA-CBER-2021-5683-0023894